Applicability of the shorter ‘Bangladesh regimen’ in high multidrug-resistant tuberculosis settings

https://doi.org/10.1016/j.ijid.2016.10.021Get rights and content
Under a Creative Commons license
open access

Highlights

  • Multidrug-resistant and extensively drug-resistant tuberculosis (MDR- and XDR-TB) is considered a serious threat to TB control and elimination.

  • The World Health Organization recommends a new shorter MDR-TB regimen in its 2016 MDR-TB guidelines.

  • The shorter MDR-TB regimen is likely to impact the number of patients treated and improve adherence.

  • Recent evidence from Europe and Latin America identified the prevalence of resistance to the drugs composing the shorter MDR-TB regimen.

  • The shorter MDR-TB regimen could be prescribed to the correct patients through the systematic use of rapid MTBDRsl testing.

Summary

In spite of the recent introduction of two new drugs (delamanid and bedaquiline) and a few repurposed compounds to treat multidrug-resistant and extensively drug-resistant tuberculosis (MDR- and XDR-TB), clinicians are facing increasing problems in designing effective regimens in severe cases. Recently a 9 to 12-month regimen (known as the ‘Bangladesh regimen’) proved to be effective in treating MDR-TB cases. It included an initial phase of 4 to 6 months of kanamycin, moxifloxacin, prothionamide, clofazimine, pyrazinamide, high-dose isoniazid, and ethambutol, followed by 5 months of moxifloxacin, clofazimine, pyrazinamide, and ethambutol. However, recent evidence from Europe and Latin America identified prevalences of resistance to the first-line drugs in this regimen (ethambutol and pyrazinamide) exceeding 60%, and of prothionamide exceeding 50%. Furthermore, the proportions of resistance to the two most important pillars of the regimen – quinolones and kanamycin – were higher than 40%. Overall, only 14 out of 348 adult patients (4.0%) were susceptible to all of the drugs composing the regimen, and were therefore potentially suitable for the ‘shorter regimen’. A shorter, cheaper, and well-tolerated MDR-TB regimen is likely to impact the number of patients treated and improve adherence if prescribed to the right patients through the systematic use of rapid MTBDRsl testing.

Keywords

MDR-TB
XDR-TB
Shorter regimen
Treatment duration
Efficacy
Impact

Cited by (0)

The authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions and policies of their institutions.

1

Giovanni Sotgiu, Simon Tiberi, Rosella Centis, and Lia D’Ambrosio contributed equally.